JP2015526463A - 改善されたダプトマイシン注射用製剤 - Google Patents

改善されたダプトマイシン注射用製剤 Download PDF

Info

Publication number
JP2015526463A
JP2015526463A JP2015528010A JP2015528010A JP2015526463A JP 2015526463 A JP2015526463 A JP 2015526463A JP 2015528010 A JP2015528010 A JP 2015528010A JP 2015528010 A JP2015528010 A JP 2015528010A JP 2015526463 A JP2015526463 A JP 2015526463A
Authority
JP
Japan
Prior art keywords
daptomycin
formulation
solution
tocopheryl phosphate
tpm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015528010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526463A5 (enExample
Inventor
サティヤ・スリニヴァス・チャトラパリ
スリラマ・サルヴェスワラ・ラオ・マンダヴィリ
バブ・ジャスティン
サティヤナラヤン・スリニヴァス・メダ
Original Assignee
アギラ・スペシャルティーズ・プライベート・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アギラ・スペシャルティーズ・プライベート・リミテッド filed Critical アギラ・スペシャルティーズ・プライベート・リミテッド
Publication of JP2015526463A publication Critical patent/JP2015526463A/ja
Publication of JP2015526463A5 publication Critical patent/JP2015526463A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015528010A 2012-08-23 2013-08-22 改善されたダプトマイシン注射用製剤 Pending JP2015526463A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2452/MUM/2012 2012-08-23
IN2452MU2012 2012-08-23
PCT/IN2013/000511 WO2014045296A2 (en) 2012-08-23 2013-08-22 Improved daptomycin injectable formulation

Publications (2)

Publication Number Publication Date
JP2015526463A true JP2015526463A (ja) 2015-09-10
JP2015526463A5 JP2015526463A5 (enExample) 2016-10-06

Family

ID=54187094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015528010A Pending JP2015526463A (ja) 2012-08-23 2013-08-22 改善されたダプトマイシン注射用製剤

Country Status (12)

Country Link
US (1) US20150216928A1 (enExample)
EP (2) EP3287138A1 (enExample)
JP (1) JP2015526463A (enExample)
AU (2) AU2013319737B2 (enExample)
BR (1) BR112015003198A2 (enExample)
CA (1) CA2881121A1 (enExample)
DK (1) DK2887953T3 (enExample)
ES (1) ES2655215T3 (enExample)
NO (1) NO2887953T3 (enExample)
PT (1) PT2887953T (enExample)
SI (1) SI2887953T1 (enExample)
WO (1) WO2014045296A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE13837694T1 (de) 2012-09-11 2015-12-31 Hospira Australia Pty Ltd. Daptomycinformulierungen und Verwendungen davon
WO2018073269A1 (en) 2016-10-21 2018-04-26 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
MX2020001885A (es) 2017-08-31 2020-09-07 Xellia Pharmaceuticals Aps Formulaciones de daptomicina.
CA3170514A1 (en) 2020-03-12 2021-09-16 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol
CN112684043A (zh) * 2020-12-16 2021-04-20 南京健友生化制药股份有限公司 一种达托霉素有关物质的检测方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005194255A (ja) * 2004-01-06 2005-07-21 Shigeo Iida 内服および注射用組成物とその製法
WO2005102369A1 (ja) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. 細菌細胞壁骨格成分を含有する製剤
JP2008543788A (ja) * 2005-06-17 2008-12-04 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 担体
WO2011063419A2 (en) * 2009-11-23 2011-05-26 Cubist Pharmaceuticals Inc. Lipopeptide compositions and related methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
FR2657526B1 (fr) * 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
WO1997014705A1 (fr) * 1995-10-17 1997-04-24 Showa Denko K.K. Phosphates de tocopherol tres purs, procedes de preparation, techniques d'analyse et produits cosmetiques correspondants
CA2772660A1 (en) * 2009-09-01 2011-03-10 Northwestern University Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers
US8431539B2 (en) * 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
AU2011213557B2 (en) * 2010-02-05 2015-05-07 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA2752784A1 (en) * 2010-09-21 2012-03-21 Xellia Pharmaceuticals Aps Daptomycin formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005194255A (ja) * 2004-01-06 2005-07-21 Shigeo Iida 内服および注射用組成物とその製法
WO2005102369A1 (ja) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. 細菌細胞壁骨格成分を含有する製剤
JP2008543788A (ja) * 2005-06-17 2008-12-04 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 担体
WO2011063419A2 (en) * 2009-11-23 2011-05-26 Cubist Pharmaceuticals Inc. Lipopeptide compositions and related methods

Also Published As

Publication number Publication date
BR112015003198A2 (pt) 2017-10-10
ES2655215T3 (es) 2018-02-19
DK2887953T3 (en) 2018-01-15
WO2014045296A2 (en) 2014-03-27
WO2014045296A3 (en) 2014-10-23
AU2018204334A1 (en) 2018-07-05
AU2013319737B2 (en) 2018-08-02
EP3287138A1 (en) 2018-02-28
PT2887953T (pt) 2018-01-10
CA2881121A1 (en) 2014-03-27
NO2887953T3 (enExample) 2018-03-10
EP2887953A4 (en) 2016-05-25
SI2887953T1 (en) 2018-02-28
EP2887953B1 (en) 2017-10-11
AU2013319737A1 (en) 2015-02-05
US20150216928A1 (en) 2015-08-06
EP2887953A2 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
RU2429837C2 (ru) Фармацевтический состав таксана, твердая композиция таксана, способ получения твердой композиции таксана, композиция для солюбилизации указанной твердой композиции таксана и комплект элементов (набор) для состава таксана для инъекций
JP2015526463A (ja) 改善されたダプトマイシン注射用製剤
US20200283568A1 (en) Composition
JP6356873B2 (ja) タキサン系活性成分含有液体組成物及び液体製剤
CA2614754A1 (en) Pharmaceutical compositions comprising a tgf-beta superfamily member
CN102274176B (zh) 一种尼莫地平注射液的组合物及其制备方法与应用
NO336427B1 (no) Farmasøytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmåte og anvendelse derav
CN112823787B (zh) 一种含有美洛昔康的注射液及其制备方法
CN112402371A (zh) 一种瑞德西韦注射液及其制备方法
CN106176626B (zh) L-丙氨酸-(14-冬凌草甲素)酯胃肠外用药物组合物
WO2021170807A1 (en) Daptomycin formulation
EP2874624B1 (en) Injectable antibiotic formulations and their methods of use
TWI426929B (zh) 持續性釋放之含抗生素醫藥組合物、製備法及其應用
TW202529794A (zh) 液態西曲瑞克（Ｃｅｔｒｏｒｅｌｉｘ）組合物
WO2023209731A1 (en) Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation
AU2013290827B2 (en) Injectable antibiotic formulations and their methods of use
WO2011101865A2 (en) Stable pharmaceutical compositions of clopidogrel for parenteral delivery
WO2005123137A2 (en) Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride
EP2976063A1 (en) Parenteral formulation of fluoroquinolone antibacterial agent and method for preparation thereof
NZ613138A (en) Injectable antibiotic formulations and their methods of use
NZ613138B2 (en) Injectable antibiotic formulations and their methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181009

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181029

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20190228